Talphera, INC 8-K filings

Talphera announced Q2 2026 results, highlighting 75% enrollment in its NEPHRO CRRT study and positive inclusion of nafamostat in draft KDIGO guidelines, alongside an increased market size estimate.

Talphera announced its first quarter 2026 financial results, highlighting progress in its NEPHRO CRRT clinical study and a cash balance of $21.1 million.

Talphera, Inc. announced its fourth quarter and full year 2025 financial results, highlighted by 50% enrollment in its NEPHRO CRRT clinical study and a $4.1 million financing tranche.

Talphera, Inc. announced the completion of the third closing of its private placement, raising approximately $4.1 million in gross proceeds.

Talphera, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Talphera, Inc. announced third quarter 2025 financial results, including a $17 million financing tranche and an extended cash runway through potential Niyad PMA approval in late 2026, alongside progress in its NEPHRO study.

Talphera, Inc. stockholders approved amendments to its equity incentive and employee stock purchase plans, elected three Class II directors, and ratified its independent auditor at the 2025 Annual Meeting.

Talphera, Inc. announced the closing of a $1.6 million private placement and its successful regain of Nasdaq minimum bid price compliance.

Talphera, Inc. announced the appointment of Joseph Todisco, CEO of CorMedix Inc., to its board of directors, a move tied to a prior securities purchase agreement that includes a right of first negotiation for a potential acquisition.

Talphera, Inc. has completed a $17 million private placement, issuing common stock and pre-funded warrants, with a potential for an additional $12 million, and granted strategic investor CorMedix Inc. a board designation right and a right of first negotiation for an acquisition contingent on clinical trial success.

Talphera, a specialty pharmaceutical company, announced accelerated enrollment in its NEPHRO clinical study and reduced its 2025 expense guidance, alongside its second quarter 2025 financial results.

Talphera, Inc. has received an additional 180-day extension from Nasdaq until December 1, 2025, to regain compliance with the $1.00 minimum bid price requirement, following its transfer to The Nasdaq Capital Market.

Talphera reports Q1 2025 financial results, highlighting progress in clinical study site activation and a recent private placement financing.

Talphera, Inc. has entered into a securities purchase agreement for a $14.7 million private placement to fund its Niyad NEPHRO CRRT study and for general working capital.

Talphera reports FDA agreement to reduce patient enrollment in the NEPHRO CRRT study, secures up to $14.8 million in financing, and anticipates study completion by the end of 2025.

Talphera, Inc. has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement for continued listing.

Talphera, Inc. received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement, putting its listing status at risk.

Talphera reported its third quarter 2024 financial results, highlighting progress in its NEPHRO CRRT study and a cash balance of $11.1 million.

Talphera, Inc. has amended its securities purchase agreement with Nantahala Management, extending the deadline for achieving precedent conditions to June 30, 2025, and introducing a clause that releases purchasers from their obligation if the company secures equity financing.

Talphera has begun screening patients for its NEPHRO CRRT study and reported a net loss of $3.8 million for the second quarter of 2024.

Talphera Inc. stockholders approved amendments to the company's 2020 Equity Incentive Plan and 2011 Employee Stock Purchase Plan at the 2024 Annual Meeting.

Talphera reported its first quarter 2024 financial results, provided a corporate update, and announced the hiring of a new Chief Development Officer.

Talphera Inc. has set June 24, 2024, for its annual shareholder meeting and established deadlines for shareholder proposals and director nominations.

Talphera, formerly AcelRx Pharmaceuticals, reported its fourth quarter 2023 financial results, highlighted by a corporate rebranding and a focus on the development of its lead asset, Niyad.

Talphera, Inc. announced a reduction in its board size from ten to seven members following the resignations of three directors, while also regaining compliance with Nasdaq's minimum bid price requirement.

Talphera announces a $26 million capital commitment through a combination of royalty monetization and equity offering to fund operations through potential FDA approval of Niyad.

Talphera has sold its rights to certain future royalty and milestone payments related to DSUVIA to XOMA for $8 million.